| Date | Upside/Downside | Analyst Firm | Price Target Change | Rating Change | Previous / Current Rating |
|---|---|---|---|---|---|
| 11/10/2022 | 51.52% | Piper Sandler | $3 → $3.5 | Upgrades | Neutral → Overweight |
| 01/26/2021 | 116.45% | Canaccord Genuity | → $5 | Downgrades | Buy → Hold |
| 01/26/2021 | 94.81% | Piper Sandler | $9 → $4.5 | Downgrades | Overweight → Neutral |
| 11/05/2020 | 332.9% | Canaccord Genuity | $13 → $10 | Maintains | Buy |
| 07/16/2020 | 462.77% | Canaccord Genuity | → $13 | Initiates Coverage On | → Buy |
| 06/24/2020 | 419.48% | Piper Sandler | → $12 | Initiates Coverage On | → Overweight |
What is the target price for KORU Medical Systems (KRMD)?
The latest price target for KORU Medical Systems (NASDAQ: KRMD) was reported by Piper Sandler on November 10, 2022. The analyst firm set a price target for $3.50 expecting KRMD to rise to within 12 months (a possible 51.52% upside). 1 analyst firms have reported ratings in the last year.
What is the most recent analyst rating for KORU Medical Systems (KRMD)?
The latest analyst rating for KORU Medical Systems (NASDAQ: KRMD) was provided by Piper Sandler, and KORU Medical Systems upgraded their overweight rating.
When is the next analyst rating going to be posted or updated for KORU Medical Systems (KRMD)?
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of KORU Medical Systems, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for KORU Medical Systems was filed on November 10, 2022 so you should expect the next rating to be made available sometime around November 10, 2023.
Is the Analyst Rating KORU Medical Systems (KRMD) correct?
While ratings are subjective and will change, the latest KORU Medical Systems (KRMD) rating was a upgraded with a price target of $3.00 to $3.50. The current price KORU Medical Systems (KRMD) is trading at is $2.31, which is out of the analyst's predicted range.